Dr. Kaveh Kahen is currently the CEO of the Advion group. For nearly three decades, Advion has been focused on delivering customer-focused life science solutions including compact mass spectrometers. Dr. Kahen has more than 20 years of global experience delivering profitable growth in highly competitive life sciences, analytical testing, and analytical instrumentation markets. Prior to joining Advion, Dr. Kahen held various R&D and business leadership positions at AB SCIEX, PerkinElmer, and more recently as the co-founder and CEO of Sigma Analytical Services, Canada’s premier medical cannabis testing and consulting company. Dr. Kahen received his Ph.D. in the field of analytical chemistry from The George Washington University. He then joined AB SCIEX and was responsible for design and development of novel technologies and instrument platforms including the NexION™ 300 ICP-MS, which was acquired and introduced by PerkinElmer in 2010. At PerkinElmer, he became the head of Global R&D, managing early stage innovation projects for all analytical platforms. Subsequently, Dr. Kahen was appointed as the Global General Manager of the Mass Spectrometry business unit where he was responsible for several successful M&As and the introduction of new LC-MS/MS and ICP-MS platforms and the company’s successful entry into the Chinese mass spectrometry market.